Ezetimibe/Simvastatin Combination in Proteinuric Nephropathy
Status:
Unknown status
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether, in patients with chronic proteinuric
nephropathy and dyslipidemia, ezetimibe-simvastatin combined therapy is more effective than
statin alone to achieve the optimum lipid control, and if this translates to an improvement
of the markers of vascular damage. Thirty hypertensive patients in stable therapy with RAS
inhibitors, with low-density lipoprotein (LDL) cholesterol superior to 100 mg/ml, are treated
with three different hypolipidemic regimens: Simvastatin alone (40 mg/day) or
ezetimibe/simvastatin combined therapy (10/20 or 10/40 mg/day).